Nofrattil (Alendronic Acid)

Alendronic Acid, the active ingredient in Nofrattil, is a bisphosphonate presented as an oral tablet for oral use. It is employed to treat osteoporosis in postmenopausal women, to prevent osteoporotic fractures, and to manage Paget's disease of bone.

GNH USA supplies Nofrattil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards, maintains regulatory certifications, and provides reliable logistics for cross‑border distribution. Our network ensures timely delivery and supports pharmacovigilance activities in partner institutions.

Nofrattil, a bisphosphonate, is indicated for conditions involving excessive bone resorption.

- Osteoporosis in postmenopausal women: reduces bone loss and lowers fracture risk. - Prevention of osteoporotic fractures: strengthens bone density to help avoid vertebral and hip fractures. - Paget's disease of bone: normalizes abnormal bone remodeling and alleviates associated pain.

Alendronic Acid may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal irritation: abdominal discomfort, dyspepsia, or nausea. - Esophageal discomfort: heartburn or difficulty swallowing. - Musculoskeletal pain: bone, joint, or muscle aches. - Flu‑like symptoms: transient fever or fatigue after the first dose.

Serious or Rare Side Effects: - Osteonecrosis of the jaw: exposed bone and pain in the jaw area. - Atypical femur fracture: sudden thigh or groin pain with possible fracture. - Severe esophageal ulceration or stricture: persistent pain or bleeding. - Hypocalcemia: low blood calcium levels causing muscle cramps or tingling. - Acute renal impairment: sudden decrease in kidney function. - Anaphylactic reaction: hives, swelling, or difficulty breathing.

Before prescribing Nofrattil, clinicians should consider several precautionary measures to minimize risk. - Assess renal function: ensure creatinine clearance meets recommended limits. - Verify calcium and vitamin D intake: adequate supplementation reduces hypocalcemia risk. - Instruct on administration: swallow tablet with a full glass of water on an empty stomach. - Avoid lying down: remain upright for at least 30 minutes after dosing. - Review concomitant medications: consider potential interactions with antacids or supplements. - Monitor for esophageal symptoms: discontinue if persistent pain or difficulty swallowing occurs. - Store below 25°C: keep in the original packaging, protect from moisture and heat.

Alendronic Acid can interact with other medicines, affecting absorption or safety.

Major Interactions (Avoid): - Calcium, iron, magnesium, or antacid supplements taken within 30 minutes: markedly reduce drug absorption. - Concurrent use of other bisphosphonates or potent bone‑resorbing agents: increase risk of oversuppression. - Systemic corticosteroids combined with oral bisphosphonates: heightened chance of osteonecrosis of the jaw.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics: may exacerbate renal toxicity. - Loop diuretics: can alter calcium balance, requiring monitoring. - Warfarin: potential for fluctuating INR values, necessitating closer coagulation checks.